Avanos Medical, Inc.

$ 24.94 0.28 %

Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.

CEO: David C. Pacitti - https://avanos.com

Price objectif

$23 -7.78 %

Recommandation

Hold

DCF

$ -17.10

Loading data...

AVNS vs S&P500

Loading data...

No data available.

Quick ratio

1.40

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-15.59

may indicate that the company is undervalued or has poor growth prospects.

EPS

-1.60

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-8.91 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-6.03 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

10.90

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.18

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.16

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
2.29 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.50 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.13 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.